[show abstract][hide abstract] ABSTRACT: The Spallation Neutron Source (SNS) is an accelerator-based neutron source being built in Oak Ridge, Tennessee, by the U.S. Department of Energy. The SNS will provide the most intense pulsed neutron beams in the world for scientific research and industrial development. CPI is supporting the effort by providing 550 kW pulsed klystrons for the super-conducting portion of the accelerator. The primary output power requirements are 550 kW peak, 49.5 kW average at 805 MHz, with an electron beam-to-rf conversion efficiency of 65% and an rf gain of 50 dB. A total of 73 units are on order. Through April 2003, eighteen units have been factory-tested. Performance specifications, computer model predictions, and operating results will be presented.
Particle Accelerator Conference, 2003. PAC 2003. Proceedings of the; 06/2003
[show abstract][hide abstract] ABSTRACT: Eosinophilia is not uncommon among returning travelers; however, the optimal diagnostic and therapeutic approach in travelers, as opposed to immigrants and refugees, is not clearly established. This was a retrospective case series. All returning travelers from developing countries presenting at the post-travel clinic with eosinophilia (>or= 500 cells/mcl) during 1994-2006 were evaluated. Data were compared with other referrals to the post-travel clinic and with a random sample of a pre-travel clinic. Of the 955 returning travelers evaluated during the study period, 82 (8.6%) had eosinophilia, and 44 (4.4%) were diagnosed with schistosomiasis. Another 38 (4.2%) cases presented with non-schistosomal eosinophilia (NSE), among whom a definite parasitologic diagnosis was achieved in only 23.7%. However, an empiric course of albendazole led to a clinical improvement in 90% of NSE cases. Helminthic disease probably accounts for the majority of cases of post-travel eosinophilia. Empiric albendazole therapy should be offered to undiagnosed NSE patients.
The American journal of tropical medicine and hygiene 05/2008; 78(5):702-9. · 2.53 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.